[14C]-DNL343
- Generic Name
- [14C]-DNL343
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06281158
- Locations
- 🇺🇸
Clinical Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath